Cancer vaccines

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Butterfield, Lisa H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CANCER VACCINE; CD8 ANTIGEN; DENDRITIC CELL VACCINE; ONCOFETAL ANTIGEN; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; PROTEIN DERIVATIVE; TUMOR ANTIGEN; TUMOR CELL VACCINE; VIRUS VACCINE; VIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CD8+ T LYMPHOCYTE; CRYOABLATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL TECHNOLOGY; MUTATION; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT RESPONSE; TUMOR ABLATION; TUMOR CELL; TUMOR IMMUNITY; VIRUS INFECTION; ABLATION THERAPY; ACTIVE IMMUNIZATION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; NEOPLASMS;

ABLATION TECHNIQUES; ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD8; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 84930640786     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h988     Document Type: Review

References (159)

1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
2. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8.
3. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983;9:689-96.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
5. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259-71.
6. Townsend KN, Spowart JE, Huwait H, et al. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. PLoS One 2013;8:e82406.
7. Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumorspecific T-cell responses. Cancer Res 2006;66:1139-46.
8. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8:151-60.
9. WHO. Cancer fact sheet. 2015. www.who.int/mediacentre/factsheets/fs297/en/.
10. American Cancer Society. Cancer facts and figures 2014. www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/.
11. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;91:6458-62.
12. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
13. Coulie PG, Brichard V, Van Pel, A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
14. Traversari C, van der Bruggen, P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7.
15. Finn, OJ, Binder, RJ, Brickner, AG, et al. Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O, Seliger B, eds. Tumor-associated antigens: Identification, characterization and clinical applications. Wiley-VCH Verlag, GmbH & Co, 2009:23-43.
16. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 1994;91:9461-5.
17. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucinbased immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
18. Bakker AB, Marland G, de Boer, AJ, et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995;55:5330-4.
19. Boon T, Cerottini JC, Van den Eynde, B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
20. Vollmer CM Jr, Eilber FC, Butterfield LH, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999;59:3064-7.
21. Butterfield LH, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alphafetoprotein. Cancer Res 1999;59:3134-42.
22. Irie RF, Giuliano AE, Morton DL. Oncofetal antigen: A tumor-associated fetal antigen immunogenic in man. J Natl Cancer Inst 1979;63:367-73.
23. Coggin JH Jr, Barsoum AL, Rohrer JW. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res 1999;19:5535-42.
24. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.
25. Vonderheide RH, Nathanson KL. Immunotherapy at large: The road to personalized cancer vaccines. Nat Med 2013;19:1098-100.
26. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641-5.
27. Overwijk WW, Wang E, Marincola FM, et al. Mining the mutanome: developing highly personalized immunotherapies based on mutational analysis of tumors. J Immunother Cancer 2013; published online 29 Jul.
28. Lehmann PV, Forsthuber T, Miller A, et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-7.
29. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003;9:998-1008.
30. Ribas A, Glaspy JA, Lee Y, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 2004;27:354-67.
31. Ribas A, Timmerman JM, Butterfield LH, et al. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003;24:58-61.
32. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptidebased vaccines. J Clin Oncol 2002;20:2624-32.
33. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011;60:433-42.
34. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-8.
35. Hu Y, Petroni GR, Olson WC, et al. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 2014;63:779-86.
36. Krauze MT, Tarhini A, Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 2011;33:385-91.
37. Gogas H, Ioannovich J, Dafni U. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
38. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013;39:1-10.
39. Kiertscher SM, Luo J, Dubinett SM, et al. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-76.
40. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
41. Zhao X, Bose A, Komita H, et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol 2012;188:1782-8.
42. Komita H, Zhao X, Taylor JL, et al. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Res 2008;68:8076-84.
43. Disis ML, Gralow JR, Bernhard H, et al. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 1996;156:3151-8.
44. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-51.
45. Slingluff CL Jr, Lee S, Zhao F, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 2013;19:4228-38.
46. Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014;32:2050-8.
47. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinicpolycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.
48. Fourcade J, Kudela P, Andrade Filho PA, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008;31:781-91.
49. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169- 77.
50. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
51. Rosenberg S, Yang J, Kammula U, et al. Different adjuvanticity of incomplete Freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother 2010;33:557-658.
52. Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72.
53. Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013;2:e26621.
54. Welters MJ, Kenter GG, de Vos van Steenwijk, PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010;107:11895-9.
55. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV- 16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
56. Rosalia RA, Quakkelaar ED, Redeker A, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol 2013;43:2554-65.
57. Hirschler B. 2-GSK cancer vaccine fails again but testing continues. Reuters 2014. www.reuters.com/article/2014/03/20/gsk-vaccineidUSL6N0MH1IR20140320.
58. Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 2011;17:343-50.
59. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011;29:2924-32.
60. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-6.
61. Disis ML, Gad E, Herendeen DR, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 2013;6:1273-82.
62. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013;6:18-26.
63. Palucka K, Ueno H, Fay J, et al. Dendritic cells and immunity against cancer. J Intern Med 2011;269:64-73.
64. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77.
65. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48.
66. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
67. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
68. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
69. Van Tendeloo, VF, Van de Velde, A, Van Driessche, A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010;107:13824-9.
70. Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013;19:3640-8.
71. Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013;2:e25771.
72. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
73. McBride WH, Thacker JD, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992;52:3931-7.
74. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998;95:13141-6.
75. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-31.
76. Tani K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 2004;10:799-816.
77. Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23:8978-91.
78. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 2012;18:858-68.
79. Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol 2012;39: 311-22.
80. Chakraborty NG, Sporn JR, Tortora AF, et al. Immunization with a tumorcell- lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998;47:58-64.
81. Geiger J, Hutchinson R, Hohenkirk L, et al. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000;356:1163-5.
82. Barth RJ Jr, Fisher DA, Wallace PK, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: Tumor-specific immune responses are associated with improved survival. Clin Cancer Res 2010;16:5548-56.
83. Kim TS, Chopra A, O-Sullivan IS, et al. Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: enrichment of the vaccine for immunotherapeutic cells. J Immunother 2006;29:261-73.
84. Meng WS, Butterfield LH, Ribas A, et al. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:8782-6.
85. Butterfield LH, Economou JS, Gamblin TC, et al. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med 2014;12:86.
86. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17-25.
87. Schumacher L, Ribas A, Dissette VB, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004;27:191-200.
88. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1- engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31:294-309.
89. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther 2000;11:797-806.
90. Engelmayer J, Larsson M, Subklewe M, et al. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion. J Immunol 1999;163:6762-8.
91. Salio M, Cella M, Suter M, et al. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol 1999;29:3245-53.
92. Madan RA, Bilusic M, Heery C, et al. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol 2012;39:296-304.
93. Smith MR, Kantoff PW. Changes in PSA kinetics after DNA vaccine therapy-not so fast! J Clin Oncol 2010;28:e58.
94. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74.
95. Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013;19:2734-44.
96. Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:9991-8.
97. John LB, Howland LJ, Flynn JK, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012;72:1651-60.
98. Li J, O'Malley M, Sampath P, et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012;14:1115-21.
99. Kaufman HL, Bines SD. OPTIM trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010;6:941-9.
100. Ross M, Ingemar R, Puzanov A, et al. Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma. J Clin Oncol 2014;32(5 suppl): 9026.
101. Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013;57:1448-57.
102. Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 2010;138:1931-42.
103. Huang X, Yuan F, Liang M, et al. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. PLoS One 2012;7:e41632.
104. Xia JZ, Xie FL, Ran LF, et al. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med Biol 2012;38:1363-71.
105. Finley DS, Pouliot F, Shuch B, et al. Ultrasound-based combination therapy: Potential in urologic cancer. Expert Rev Anticancer Ther 2011;11:107-13.
106. Ayaru L, Pereira SP, Alisa A, et al. Unmasking of alpha-fetoproteinspecific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 2007;178:1914-22.
107. Gravante G, Sconocchia G, Ong SL, et al. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int 2009;29:18-24.
108. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
109. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21.
110. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010;70:3052-61.
111. Tsavaris N, Kosmas C, Vadiaka M, et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21-7.
112. Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014;3:e27878.
113. Demaria S, Pilones KA, Vanpouille-Box C, et al. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 2014;182:170-81.
114. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004;58:862-70.
115. Cotter SE, Dunn GP, Collins KM, et al. Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: Potential role of induced antitumor immunity. Arch Dermatol 2011;147:870-2.
116. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31.
117. Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012;83: 1306-10.
118. Vacchelli E, Vitale I, Tartour E, et al. Trial watch: Anticancer radioimmunotherapy. Oncoimmunology 2013;2:e25595.
119. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31.
120. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-9.
121. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403.
122. Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: Are we making progress? Front Immunol 2013;4:454.
123. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625-35.
124. Eshhar Z, Waks T, Bendavid A, et al. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248:67-76.
125. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118: 4817-28.
126. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-4.
127. Drake AC. Of mice and men: What rodent models don't tell us. Cell Mol Immunol 2013;10:284-5.
128. Di Nicolantonio, F, Bardelli A. Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing? Clin Cancer Res 2013;19:2794-6.
129. Meng WS, Butterfield LH, Ribas A, et al. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:8782-6.
130. Meng WS, Butterfield LH. Activation of antigen-presenting cells by DNA delivery vectors. Expert Opin Biol Ther 2005;5:1019-28.
131. Conry RM, LoBuglio AF, Loechel F, et al. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995;2:33-8.
132. Kumar V, Sercarz E. Genetic vaccination: The advantages of going naked. Nat Med 1996;2:857-9.
133. Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8: 2782-7.
134. Rosenberg SA, Yang JC, Sherry RM, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003;14:709-14.
135. Radkevich-Brown O, Piechocki MP, Back JB, et al. Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression. Cancer Immunol Immunother 2010;59:409-17.
136. Diaz CM, Chiappori A, Aurisicchio, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013;11:62.
137. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38:208-17.
138. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10:909-15.
139. Timmerman JM, Levy R. Cancer vaccines: Pessimism in check. Nat Med 2004;10:1279; author reply 1279-80.
140. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013;39:49-60.
141. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013;13:525-41.
142. Butterfield LH, Palucka AK, Britten CM, et al. Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 2011;17:3064-76.
143. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
144. Dancey JE, Dobbin KK, Groshen S, et al. Biomarkers task force of the NCI investigational drug steering committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010;16:1745-55.
145. Janetzki S, Panageas KS, Ben-Porat L, et al. Elispot proficiency panel of the CVC immune assay working group. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008;57:303-15.
146. Britten CM, Janetzki S, Ben-Porat L, et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009;58:1701-13.
147. Janetzki S, Britten CM, Kalos M, et al. "MIATA"-minimal information about T cell assays. Immunity 2009;31:527-8.
148. Janetzki S, Britten CM. The impact of harmonization on ELISPOT assay performance. Methods Mol Biol 2012;792:25-36.
149. Schaefer C, Butterfield LH, Lee S, et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer 2012;131:874-84.
150. Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006;203:2865-77.
151. Sondergaard K, Schou G. Prognostic factors in primary cutaneous malignant melanoma. Am J Dermatopathol 1985;7(suppl):1-4.
152. Fridman WH, Pages F, Sautes-Fridman C, et al. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
153. Erdag G, Schaefer JT, Slingluff CL Jr, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012;72:1070-80.
154. Harlin H, Meng Y, Gajewski TF, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69:3077-85.
155. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res 2014;20:1601-9.
156. Tarhini AA, Butterfield LH, Shuai Y, et al. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 2012;35:702-10.
157. Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014;9:e87705.
158. Butterfield L, Vujanovic L, Pardee A. Approaches to immunologic monitoring of clinical trials. In: The tumor immunoenvironment. Springer, 2013:663-94.
159. Nagato T, Lee YR, Harabuchi Y, Celis E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res 2014;20:1223-34.